Background and objectivesThe overexpression mutation of EGFRs are associated with various types human cancers. Epidermal growth factor receptor variant III (EGFRvIII) is one the most notable EGFR mutations, exclusively present in cancer cells, making it a potential therapeutic target. The study aims to determine whether recombinant immunotoxin 86 (rIT86) can effectively kill EGFRvIII-expressing...

Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized scoring methods. To address these limitations, we assessed whether automated image analysis of immunohistochemically stained tissue microarray...

We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. She was diagnosed with congestive heart failure caused by the osimertinib. In contrast to trastuz...